DDInter1197 DDInter1627
Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures. One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route. Metoclopramide was initially approved by the FDA in 1980.
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Metoclopramide {u} (Compound) causes {v} (Side Effect) Rash
Rash {u} (Side Effect) is caused by {v} (Compound) Rufinamide
Metoclopramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levetiracetam
Levetiracetam {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Rufinamide
Metoclopramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levetiracetam
Levetiracetam {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Rufinamide
Metoclopramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Phenytoin {u} (Compound) binds {v} (Gene) SCN2A
SCN2A {u} (Gene) is bound by {v} (Compound) Rufinamide
Metoclopramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fosphenytoin
Fosphenytoin {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Rufinamide
Metoclopramide {u} (Compound) palliates {v} (Disease) migraine
migraine {u} (Disease) resembles {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Rufinamide
Metoclopramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fosphenytoin
Fosphenytoin {u} (Compound) binds {v} (Gene) SCN5A
SCN5A {u} (Gene) is bound by {v} (Compound) Rufinamide
Metoclopramide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is associated with {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Rufinamide
Metoclopramide {u} (Compound) palliates {v} (Disease) migraine
migraine {u} (Disease) is associated with {v} (Gene) SCN2A
SCN2A {u} (Gene) is bound by {v} (Compound) Rufinamide
Metoclopramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fosphenytoin
Fosphenytoin {u} (Compound) causes {v} (Side Effect) Rash
Rash {u} (Side Effect) is caused by {v} (Compound) Rufinamide
Metoclopramide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Rufinamide (Compound)
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Levetiracetam and Levetiracetam (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Rufinamide (Compound)
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Levetiracetam and Levetiracetam (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Rufinamide (Compound)
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) binds SCN2A (Gene) and SCN2A (Gene) is bound by Rufinamide (Compound)
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Rufinamide (Compound)
Metoclopramide (Compound) palliates migraine (Disease) and migraine (Disease) resembles epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Rufinamide (Compound)
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin (Compound) binds SCN5A (Gene) and SCN5A (Gene) is bound by Rufinamide (Compound)
Metoclopramide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is associated with epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Rufinamide (Compound)
Metoclopramide (Compound) palliates migraine (Disease) and migraine (Disease) is associated with SCN2A (Gene) and SCN2A (Gene) is bound by Rufinamide (Compound)
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Rufinamide (Compound)